An exploratory clinical trial of bortezomib in patients with lower risk myelodysplastic syndromes
Sign Up to like & getrecommendations! Published in 2017 at "American Journal of Hematology"
DOI: 10.1002/ajh.24746
Abstract: Myelodysplastic syndromes (MDSs) are characterized by ineffective hematopoiesis and an increased risk of transformation. Few effective therapies are available for lower risk MDS patients, especially after the failure of hypomethylating agents. MDS progenitor cells are… read more here.
Keywords: myelodysplastic syndromes; risk; lower risk; bortezomib ... See more keywords
Cosm-nutraceutical nanovesicles for acne treatment: Physicochemical characterization and exploratory clinical experimentation.
Sign Up to like & getrecommendations! Published in 2020 at "International journal of pharmaceutics"
DOI: 10.1016/j.ijpharm.2020.119092
Abstract: The full exploration of the 'nutraceuticals' therapeutic potential in cosmetics has been hindered by their poor stratum corneum permeation. Therefore, the aim of the present study was to formulate a nutraceutical; quercetin, in novel vitamin… read more here.
Keywords: nutraceutical nanovesicles; nanovesicles acne; treatment; cosm nutraceutical ... See more keywords
Robust time selection for interim analysis in the Bayesian phase 2 exploratory clinical trial.
Sign Up to like & getrecommendations! Published in 2023 at "Journal of biopharmaceutical statistics"
DOI: 10.1080/10543406.2023.2208665
Abstract: In phase 2 clinical trials, we expect to make a right Go or No-Go decision during the interim analysis (IA) and make this decision at the right time. The optimal time for IA is usually… read more here.
Keywords: time; exploratory clinical; interim analysis; phase ... See more keywords